Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In 11 of 18 (61%) poorly differentiated (Gleason score, 8-10) prostatic carcinoma specimens, there was strong expression of PPARalpha compared with 4 of 12 Gleason score 7 tumors and 2 of 11 Gleason score 3-6 tumors (P < 0.01).
|
10955810 |
2000 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Here, we report for the first time that in two different human bladder cancer cell lines, RT4 (derived from grade I tumor) and T24 (derived from grade III tumor), VEGF (mRNA and protein) is differentially up-regulated by the three PPAR isotypes.
|
11980898 |
2002 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
ANGPTL4, originally identified as a peroxisome proliferator-activated receptor alpha and gamma target gene, has potential for use as a new diagnostic tool and a potential therapeutic target, modulating angiogenesis both in tumors and in ischemic tissues.
|
12707035 |
2003 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Here, we show that PPARalpha controls SMC cell-cycle progression at the G1/S transition by targeting the cyclin-dependent kinase inhibitor and tumor suppressor p16(INK4a) (p16), resulting in an inhibition of retinoblastoma protein phosphorylation.
|
16239970 |
2005 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In the present study, we show that tumour promoter PMA-mediated induction of genes that are significantly associated with inflammation, tumour growth and metastasis, such as COX-2 (cyclo-oxygenase 2) and VEGF (vascular endothelial growth factor), is inhibited by PPARalpha ligands in the human colorectal carcinoma cell line SW620.
|
16343055 |
2006 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These data suggest that the decreased drug sensitivity of PPAR gamma1(tr)-expressing cells may be associated with increased tumor aggressiveness and poor clinical prognosis of patients.
|
17473186 |
2007 |
Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
To study the role of the PPARalpha receptor and of its Cyp2c epoxygenase gene target in tumorigenesis, we treated mice injected with tumor cells with Wy-14,643, a PPARalpha-selective ligand.
|
17405874 |
2007 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
PPARalpha activation causes inhibition of migration of melanoma cells and anchorage-independent growth, whereas primary tumor growth remains unaltered.
|
18092840 |
2008 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, both genetic abrogation of PPARalpha as well as its activation by ligands cause tumor suppression via overlapping antiangiogenic pathways.
|
18199835 |
2008 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Optimal cutoff values were determined for each relative expression ratio (RER) (RER = PPAR expression of tumor/PPAR expression of normal mucosa) of PPAR, and patients were divided into two groups as follows (PPAR staging): patients with elevated RERs of PPAR gamma (> 2.0) or PPAR delta (> 1.0) were termed Group H, and patients showing none of these elevated RERs of PPARs were termed Group L. Prognostic significance was analyzed by univariate and Kaplan-Meier analyses.
|
19283612 |
2009 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our findings may also reveal the possibility of using the level of endogenous PPARγ ligands and the activities of PPARγ or PPARα as tumor markers for lung cancer.
|
20081051 |
2010 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Administration of a novel NOX-specific inhibitor reduced angiogenesis and tumor growth in vivo in a PPARα dependent manner.
|
21326871 |
2011 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Activation of peroxisome proliferator-activated receptor α (PPARα) has been demonstrated to inhibit tumor growth and angiogenesis, yet the mechanisms behind these actions remain to be characterized.
|
22932900 |
2012 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
PPARα is a nuclear receptor protein that functions as a transcription factor for genes including those encoding enzymes involved in energy metabolism; while PPARα has been reported to regulate tumor growth in several cancers, it has not been evaluated in RCC.
|
23951092 |
2013 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Although PPARα expression was also increased in the n-3 PUFA-enriched diet group under docetaxel treatment, it is only the expression of PPARβ mRNA that correlated with the regression of mammary tumors: those that most regressed displayed the lowest PPARβ mRNA expression.
|
23906790 |
2013 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In conclusion, this study demonstrates that loss of expression of GMPR2 and PPARα is associated with BP at the protein level; indicating that they may play a role in carcinogenesis of this molecularly complex and clinically important subtype.
|
23208589 |
2013 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Based on these studies, it was demonstrated that the liver tumors were mediated by a mode of action (MoA) involving nuclear receptors (NRs) through the following key events: (1) CAR and PPAR-α receptor activation, (2) increased hepatocellular proliferation, eventually leading to (3) hepatocellular tumors.
|
25092647 |
2014 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
PFCAs, especially those having longer carbon chain lengths (≥C6), are associated with developmental and hormonal effects, immunotoxicity, and promote tumor growth in rodents through their role as PPARα agonists.
|
27876672 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
5) Peroxisome proliferators do not promote tumour formation in human liver as opposed to mouse liver because of structural and functional differences between human and mouse PPARα.
|
28077274 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Importantly, genetic knockouts of PPARα have been shown to be protected against tumor growth in a variety of syngeneic tumors models.
|
28483457 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
PPARα was previously indicated by us as a potential therapeutic target for this neoplasm, due to the malignancy grade dependency of its expression, being particularly abundant in GB.
|
27736000 |
2017 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We further confirmed that depletion of PPARα resulted in low CPT1C expression and then inhibited proliferation and induced senescence of MDA-MB-231 and PANC-1 tumor cell lines in a CPT1C-dependent manner, while forced PPARα overexpression promoted cell proliferation and reversed cellular senescence.
|
28334197 |
2017 |
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Activation of peroxisome proliferator-activated receptor alpha (PPARα) has been reported to disrupt tumour metabolism and to promote anticancer activity through interfering with the Warburg effect.
|
28453233 |
2017 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Upstream regulator analysis highlighted transcriptional regulation by peroxisome proliferator-activated receptor alpha (PPARα) in the liver and kidney and by tumor protein/suppressor p53 (TP53) in the thymus, spleen, and liver.
|
30186752 |
2018 |
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
PPARα expression was unrelated to gonadotroph differentiation in NFPA, but positively correlated with tumour volume in PRL-PA.
|
30021235 |
2018 |